Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2018

08.06.2018 | Breast Oncology

Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial

verfasst von: Walter Paul Weber, MD, Christoph Tausch, MD, Stefanie Hayoz, PhD, Mathias Konrad Fehr, MD, Karin Ribi, PhD, Hanne Hawle, MD, Judith Eva Lupatsch, PhD, Klazien Matter-Walstra, PhD, Federica Chiesa, MD, Konstantin Johannes Dedes, MD, Gilles Berclaz, MD, Loic Lelièvre, MD, Thomas Hess, MD, Uwe Güth, MD, Verena Pioch, MD, Dimitri Sarlos, MD, Cornelia Leo, MD, Claudia Canonica, MD, Natalie Gabriel, MD, Jasmin Zeindler, MD, Estelle Cassoly, PhD, Christiane Andrieu, PhD, Savas Deniz Soysal, MD, Thomas Ruhstaller, MD, Peter Martin Fehr, MD, Michael Knauer, MD, PhD, for the Swiss Group for Clinical Cancer Research (SAKK)

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Several studies and a meta-analysis showed that fibrin sealant patches reduced lymphatic drainage after various lymphadenectomy procedures. Our goal was to investigate the impact of these patches on drainage after axillary dissection for breast cancer.

Methods

In a phase III superiority trial, we randomized patients undergoing breast-conserving surgery at 14 Swiss sites to receive versus not receive three large TachoSil® patches in the dissected axilla. Axillary drains were inserted in all patients. Patients and investigators assessing outcomes were blinded to group assignment. The primary endpoint was total volume of drainage.

Results

Between March 2015 and December 2016, 142 patients were randomized (72 with TachoSil® and 70 without). Mean total volume of drainage in the control group was 703 ml [95% confidence interval (CI) 512–895 ml]. Application of TachoSil® did not significantly reduce the total volume of axillary drainage [mean difference (MD) −110 ml, 95% CI −316 to 94, p = 0.30]. A total of eight secondary endpoints related to drainage, morbidity, and quality of life were not improved by use of TachoSil®. The mean total cost per patient did not differ significantly between the groups [34,253 Swiss Francs (95% CI 32,625–35,880) with TachoSil® and 33,365 Swiss Francs (95% CI 31,771–34,961) without, p = 0.584]. In the TachoSil® group, length of stay was longer (MD 1 day, 95% CI 0.3–1.7, p = 0.009), and improvement of pain was faster, although the latter difference was not significant [2 days (95% CI 1–4) vs. 5.5 days (95% CI 2–11); p = 0.2].

Conclusions

TachoSil® reduced drainage after axillary dissection for breast cancer neither significantly nor relevantly.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Droeser RA, Frey DM, Oertli D et al. Volume-controlled vs no/short-term drainage after axillary lymph node dissection in breast cancer surgery: a meta-analysis. Breast. 2009;18:109–14.CrossRefPubMed Droeser RA, Frey DM, Oertli D et al. Volume-controlled vs no/short-term drainage after axillary lymph node dissection in breast cancer surgery: a meta-analysis. Breast. 2009;18:109–14.CrossRefPubMed
2.
Zurück zum Zitat He XD, Guo ZH, Tian JH et al. Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials. Med Oncol. 2011;28(Suppl 1):S22–30.CrossRefPubMed He XD, Guo ZH, Tian JH et al. Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials. Med Oncol. 2011;28(Suppl 1):S22–30.CrossRefPubMed
3.
Zurück zum Zitat Gauthier T, Garuchet-Bigot A, Marin B et al. Lanreotide autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial. Eur J Surg Oncol. 2012;38(10):902–9.CrossRefPubMed Gauthier T, Garuchet-Bigot A, Marin B et al. Lanreotide autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial. Eur J Surg Oncol. 2012;38(10):902–9.CrossRefPubMed
4.
Zurück zum Zitat O’Hea BJ, Ho MN, Petrek JA. External compression dressing versus standard dressing after axillary lymphadenectomy. Am J Surg. 1999;177:450–3.CrossRefPubMed O’Hea BJ, Ho MN, Petrek JA. External compression dressing versus standard dressing after axillary lymphadenectomy. Am J Surg. 1999;177:450–3.CrossRefPubMed
5.
Zurück zum Zitat Shamley DR, Barker K, Simonite V, et al. Delayed versus immediate exercises following surgery for breast cancer: a systematic review. Breast Cancer Res Treat. 2005;90:263–71.CrossRefPubMed Shamley DR, Barker K, Simonite V, et al. Delayed versus immediate exercises following surgery for breast cancer: a systematic review. Breast Cancer Res Treat. 2005;90:263–71.CrossRefPubMed
6.
Zurück zum Zitat van Bemmel AJ, van de Velde CJ, Schmitz RF, et al. Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol. 2011;37:829–35.CrossRefPubMed van Bemmel AJ, van de Velde CJ, Schmitz RF, et al. Prevention of seroma formation after axillary dissection in breast cancer: a systematic review. Eur J Surg Oncol. 2011;37:829–35.CrossRefPubMed
7.
Zurück zum Zitat Cipolla C, Fricano S, Vieni S, et al. Does the use of fibrin glue prevent seroma formation after axillary lymphadenectomy for breast cancer? A prospective randomized trial in 159 patients. J Surg Oncol. 2010;101:600–3.CrossRefPubMed Cipolla C, Fricano S, Vieni S, et al. Does the use of fibrin glue prevent seroma formation after axillary lymphadenectomy for breast cancer? A prospective randomized trial in 159 patients. J Surg Oncol. 2010;101:600–3.CrossRefPubMed
8.
Zurück zum Zitat Gilly FN, Francois Y, Sayag-Beaujard AC, et al. Prevention of lymphorrhea by means of fibrin glue after axillary lymphadenectomy in breast cancer: prospective randomized trial. Eur Surg Res. 1998;30:439–43.CrossRefPubMed Gilly FN, Francois Y, Sayag-Beaujard AC, et al. Prevention of lymphorrhea by means of fibrin glue after axillary lymphadenectomy in breast cancer: prospective randomized trial. Eur Surg Res. 1998;30:439–43.CrossRefPubMed
9.
Zurück zum Zitat Ko E, Han W, Cho J, et al. Fibrin glue reduces the duration of lymphatic drainage after lumpectomy and level II or III axillary lymph node dissection for breast cancer: a prospective randomized trial. J Korean Med Sci. 2009;24:92–6.CrossRefPubMedPubMedCentral Ko E, Han W, Cho J, et al. Fibrin glue reduces the duration of lymphatic drainage after lumpectomy and level II or III axillary lymph node dissection for breast cancer: a prospective randomized trial. J Korean Med Sci. 2009;24:92–6.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ruggiero R, Procaccini E, Gili S, et al. Fibrin glue to reduce seroma after axillary lymphadenectomy for breast cancer. Min Chir. 2008;63:249–54. Ruggiero R, Procaccini E, Gili S, et al. Fibrin glue to reduce seroma after axillary lymphadenectomy for breast cancer. Min Chir. 2008;63:249–54.
11.
Zurück zum Zitat Swan MC, Oliver DW, Cassell OC, et al. Randomized controlled trial of fibrin sealant to reduce postoperative drainage following elective lymph node dissection. Br J Surg. 2011;98:918–24.CrossRefPubMed Swan MC, Oliver DW, Cassell OC, et al. Randomized controlled trial of fibrin sealant to reduce postoperative drainage following elective lymph node dissection. Br J Surg. 2011;98:918–24.CrossRefPubMed
12.
Zurück zum Zitat Taflampas P, Sanidas E, Christodoulakis M, et al. Sealants after axillary lymph node dissection for breast cancer: good intentions but bad results. Am J Surg. 2009;198:55–8.CrossRefPubMed Taflampas P, Sanidas E, Christodoulakis M, et al. Sealants after axillary lymph node dissection for breast cancer: good intentions but bad results. Am J Surg. 2009;198:55–8.CrossRefPubMed
13.
Zurück zum Zitat Carless PA, Henry DA. Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. Br J Surg. 2006;93:810–9.CrossRefPubMed Carless PA, Henry DA. Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. Br J Surg. 2006;93:810–9.CrossRefPubMed
14.
Zurück zum Zitat Buda A, Fruscio R, Pirovano C, et al. The use of TachoSil for the prevention of postoperative complications after groin dissection in cases of gynecologic malignancy. Int J Gynaecol Obstet. 2012;117:217–9.CrossRefPubMed Buda A, Fruscio R, Pirovano C, et al. The use of TachoSil for the prevention of postoperative complications after groin dissection in cases of gynecologic malignancy. Int J Gynaecol Obstet. 2012;117:217–9.CrossRefPubMed
15.
Zurück zum Zitat 15. Buda A, Ghelardi A, Fruscio R, et al. The contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after groin lymphadenectomy: a double institution observational study. Eur J Obstet Gynecol Reprod Biol. 2016;197:156–8.CrossRefPubMed 15. Buda A, Ghelardi A, Fruscio R, et al. The contribution of a collagen-fibrin patch (Tachosil) to prevent the postoperative lymphatic complications after groin lymphadenectomy: a double institution observational study. Eur J Obstet Gynecol Reprod Biol. 2016;197:156–8.CrossRefPubMed
16.
Zurück zum Zitat Di MG, Caraco C, Crispo A, et al. Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. World J Surg Oncol. 2012;10:275.CrossRef Di MG, Caraco C, Crispo A, et al. Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. World J Surg Oncol. 2012;10:275.CrossRef
17.
Zurück zum Zitat Navarro-Rodriguez E, Gomez-Luque I, Diaz-Jimenez N, et al. Effectiveness of an absorbable fibrin sealant patch to reduce lymphoceles formation after axillary lymphadenectomy for breast cancer: a matched-pair analysis. Am J Surg. 2014;208:824–30.CrossRefPubMed Navarro-Rodriguez E, Gomez-Luque I, Diaz-Jimenez N, et al. Effectiveness of an absorbable fibrin sealant patch to reduce lymphoceles formation after axillary lymphadenectomy for breast cancer: a matched-pair analysis. Am J Surg. 2014;208:824–30.CrossRefPubMed
18.
Zurück zum Zitat Pinero-Madrona A, Castellanos-Escrig G, Abrisqueta-Carrion J, et al. Prospective randomized controlled study to assess the value of a hemostatic and sealing agent for preventing seroma after axillary lymphadenectomy. J Surg Oncol. 2016;114:423–7.CrossRefPubMed Pinero-Madrona A, Castellanos-Escrig G, Abrisqueta-Carrion J, et al. Prospective randomized controlled study to assess the value of a hemostatic and sealing agent for preventing seroma after axillary lymphadenectomy. J Surg Oncol. 2016;114:423–7.CrossRefPubMed
19.
Zurück zum Zitat Gasparri ML, Ruscito I, Bolla D, et al. The efficacy of fibrin sealant patches in reducing the incidence of lymphatic morbidity after radical lymphadenectomy: a meta-analysis. Int J Gynecol Cancer. 2017;27:1283–92.CrossRefPubMed Gasparri ML, Ruscito I, Bolla D, et al. The efficacy of fibrin sealant patches in reducing the incidence of lymphatic morbidity after radical lymphadenectomy: a meta-analysis. Int J Gynecol Cancer. 2017;27:1283–92.CrossRefPubMed
20.
Zurück zum Zitat Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20:250–78. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20:250–78.
22.
Zurück zum Zitat Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23:129–38.PubMed Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. 1994;23:129–38.PubMed
23.
Zurück zum Zitat Antonio M, Pietra T, Domenico L, et al. Does LigaSure reduce fluid drainage in axillary dissection? A randomized prospective clinical trial. Ecancermedicalscience. 2007;1:61.PubMedPubMedCentral Antonio M, Pietra T, Domenico L, et al. Does LigaSure reduce fluid drainage in axillary dissection? A randomized prospective clinical trial. Ecancermedicalscience. 2007;1:61.PubMedPubMedCentral
24.
Zurück zum Zitat Chintamani, Singhal V, Singh J, et al. Half versus full vacuum suction drainage after modified radical mastectomy for breast cancer- a prospective randomized clinical trial [ISRCTN24484328]. BMC Cancer. 2005;5:11. Chintamani, Singhal V, Singh J, et al. Half versus full vacuum suction drainage after modified radical mastectomy for breast cancer- a prospective randomized clinical trial [ISRCTN24484328]. BMC Cancer. 2005;5:11.
25.
Zurück zum Zitat Classe JM, Berchery D, Campion L, et al. Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer. Br J Surg. 2006;93:820–4.CrossRefPubMed Classe JM, Berchery D, Campion L, et al. Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer. Br J Surg. 2006;93:820–4.CrossRefPubMed
26.
Zurück zum Zitat Cortadellas T, Cordoba O, Espinosa-Bravo M, et al. Electrothermal bipolar vessel sealing system in axillary dissection: a prospective randomized clinical study. Int J Surg. 2011;9:636–40.CrossRefPubMed Cortadellas T, Cordoba O, Espinosa-Bravo M, et al. Electrothermal bipolar vessel sealing system in axillary dissection: a prospective randomized clinical study. Int J Surg. 2011;9:636–40.CrossRefPubMed
27.
Zurück zum Zitat Yang Y, Gao E, Liu X, et al. Effectiveness of OK-432 (Sapylin) to reduce seroma formation after axillary lymphadenectomy for breast cancer. Ann Surg Oncol. 2013;20(5):1500–4.CrossRefPubMed Yang Y, Gao E, Liu X, et al. Effectiveness of OK-432 (Sapylin) to reduce seroma formation after axillary lymphadenectomy for breast cancer. Ann Surg Oncol. 2013;20(5):1500–4.CrossRefPubMed
28.
Zurück zum Zitat Zavotsky J, Jones RC, Brennan MB, et al. Evaluation of axillary lymphadenectomy without axillary drainage for patients undergoing breast-conserving therapy. Ann Surg Oncol. 1998;5:227–31.CrossRefPubMed Zavotsky J, Jones RC, Brennan MB, et al. Evaluation of axillary lymphadenectomy without axillary drainage for patients undergoing breast-conserving therapy. Ann Surg Oncol. 1998;5:227–31.CrossRefPubMed
29.
Zurück zum Zitat Barry M, Weber WP, Lee S, et al. Enhancing the clinical pathway for patients undergoing axillary lymph node dissection. Breast. 2012;21:440–3.CrossRefPubMed Barry M, Weber WP, Lee S, et al. Enhancing the clinical pathway for patients undergoing axillary lymph node dissection. Breast. 2012;21:440–3.CrossRefPubMed
30.
Zurück zum Zitat Baas-Vrancken Peeters MJ, Kluit AB, Merkus JW, et al. Short versus long-term postoperative drainage of the axilla after axillary lymph node dissection. A prospective randomized study. Breast Cancer Res Treat. 2005;93:271–5.CrossRefPubMed Baas-Vrancken Peeters MJ, Kluit AB, Merkus JW, et al. Short versus long-term postoperative drainage of the axilla after axillary lymph node dissection. A prospective randomized study. Breast Cancer Res Treat. 2005;93:271–5.CrossRefPubMed
31.
Zurück zum Zitat Dalberg K, Johansson H, Signomklao T, et al. A randomised study of axillary drainage and pectoral fascia preservation after mastectomy for breast cancer. Eur J Surg Oncol. 2004;30:602–9.CrossRefPubMed Dalberg K, Johansson H, Signomklao T, et al. A randomised study of axillary drainage and pectoral fascia preservation after mastectomy for breast cancer. Eur J Surg Oncol. 2004;30:602–9.CrossRefPubMed
32.
Zurück zum Zitat Gong Y, Xu J, Shao J, et al. Prevention of seroma formation after mastectomy and axillary dissection by lymph vessel ligation and dead space closure: a randomized trial. Am J Surg. 2010;200:352–6.CrossRefPubMed Gong Y, Xu J, Shao J, et al. Prevention of seroma formation after mastectomy and axillary dissection by lymph vessel ligation and dead space closure: a randomized trial. Am J Surg. 2010;200:352–6.CrossRefPubMed
33.
Zurück zum Zitat Briceno J, Naranjo A, Ciria R, et al. A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection. Arch Surg. 2010;145:482–8.CrossRefPubMed Briceno J, Naranjo A, Ciria R, et al. A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection. Arch Surg. 2010;145:482–8.CrossRefPubMed
34.
Zurück zum Zitat Fischer L, Seiler CM, Broelsch CE, et al. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery. 2011;149:48–55.CrossRefPubMed Fischer L, Seiler CM, Broelsch CE, et al. Hemostatic efficacy of TachoSil in liver resection compared with argon beam coagulator treatment: an open, randomized, prospective, multicenter, parallel-group trial. Surgery. 2011;149:48–55.CrossRefPubMed
35.
Zurück zum Zitat Frilling A, Stavrou GA, Mischinger HJ, et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg. 2005;390:114–20.CrossRefPubMed Frilling A, Stavrou GA, Mischinger HJ, et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg. 2005;390:114–20.CrossRefPubMed
36.
Zurück zum Zitat Genyk Y, Kato T, Pomposelli JJ, et al. Fibrin sealant patch (Tachosil) vs oxidized regenerated cellulose patch (Surgicel original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg. 2016;222:261–8.CrossRefPubMed Genyk Y, Kato T, Pomposelli JJ, et al. Fibrin sealant patch (Tachosil) vs oxidized regenerated cellulose patch (Surgicel original) for the secondary treatment of local bleeding in patients undergoing hepatic resection: a randomized controlled trial. J Am Coll Surg. 2016;222:261–8.CrossRefPubMed
37.
Zurück zum Zitat Kakaei F, Seyyed Sadeghi MS, Sanei B, et al. A randomized clinical trial comparing the effect of different haemostatic agents for haemostasis of the liver after hepatic resection. HPB Surg. 2013;2013:587–608.CrossRef Kakaei F, Seyyed Sadeghi MS, Sanei B, et al. A randomized clinical trial comparing the effect of different haemostatic agents for haemostasis of the liver after hepatic resection. HPB Surg. 2013;2013:587–608.CrossRef
38.
Zurück zum Zitat Rickenbacher A, Breitenstein S, Lesurtel M, et al. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery—a systematic review. Expert Opin Biol Ther. 2009;9:897-907.CrossRefPubMed Rickenbacher A, Breitenstein S, Lesurtel M, et al. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery—a systematic review. Expert Opin Biol Ther. 2009;9:897-907.CrossRefPubMed
39.
Zurück zum Zitat Berger A, Tempfer C, Hartmann B, et al. Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study. Breast Cancer Res Treat. 2001;67:9–14.CrossRefPubMed Berger A, Tempfer C, Hartmann B, et al. Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study. Breast Cancer Res Treat. 2001;67:9–14.CrossRefPubMed
Metadaten
Titel
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial
verfasst von
Walter Paul Weber, MD
Christoph Tausch, MD
Stefanie Hayoz, PhD
Mathias Konrad Fehr, MD
Karin Ribi, PhD
Hanne Hawle, MD
Judith Eva Lupatsch, PhD
Klazien Matter-Walstra, PhD
Federica Chiesa, MD
Konstantin Johannes Dedes, MD
Gilles Berclaz, MD
Loic Lelièvre, MD
Thomas Hess, MD
Uwe Güth, MD
Verena Pioch, MD
Dimitri Sarlos, MD
Cornelia Leo, MD
Claudia Canonica, MD
Natalie Gabriel, MD
Jasmin Zeindler, MD
Estelle Cassoly, PhD
Christiane Andrieu, PhD
Savas Deniz Soysal, MD
Thomas Ruhstaller, MD
Peter Martin Fehr, MD
Michael Knauer, MD, PhD
for the Swiss Group for Clinical Cancer Research (SAKK)
Publikationsdatum
08.06.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6556-9

Weitere Artikel der Ausgabe 9/2018

Annals of Surgical Oncology 9/2018 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.